LLY compared with SPRY: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

SPRYARS Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

SPRYARS Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

SPRY: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

LLY, solidSPRY, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only SPRY 18

—ALKunlistedsupplier

—ALK U.Sunlistedsupplier

—Recordati Irelandunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Aegis Therapeutics

unlistedsupplier

14 more · SPRY chain ›

LLYELI Lilly & Co

1,407.25▼−0.27%· post 1,407.00· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

SPRYARS Pharmaceuticals, Inc.

3.05▼−0.16%· post 3.05· delayed

After hoursNov 3 '26delayed

Mkt cap$303.3MRevenue$34MQ2 FY26Revenue$84MFY25

Compare

After hoursNov 3 '26delayed

LLYELI Lilly & Co

SPRYARS Pharmaceuticals, Inc.

1,407.25▼−0.27%post 1,407.00delayed

Price

3.05▼−0.16%post 3.05delayed

$1.3T

Mkt cap

$303.3M

Q3 FY26$24.4B

Revenue

$34MQ2 FY26

FY25$65.2B

Revenue

$84MFY25

LLY1,407.25▼−0.27%vsSPRY3.05▼−0.16%After hoursNov 3 '26delayed